Morgan Keegan Reiterates Outperform on Emeritus Corp. (ESC)

Morgan Keegan is out with a research report this morning, where it reiterates its Outperform rating on Emeritus Corp. ESC; it has a $22.00 price target on the stock. The MK analysts cited the company’s recent earnings report, which beat estimates due to better-than-expected revenues and margins and lower-than-expected capital expenses. Important to note, was that same-store occupancy improved sequentially, annual pricing improved 3.1%, discounting declined, and operating margin improved markedly from depressed levels in the prior two quarters. The MK analysts raised their 2010 our 2010 CFFO estimate from $1.13 to $1.23 and the 2011 estimate from $1.42 to $1.47. As for valuation, they remarked, “Our price target for Emeritus is $22. We base this on a near-term growth-rate target P/CFFO multiple of 15 applied to our 2011 CFFO estimate of $1.47. We believe this multiple is warranted given strong near-term growth prospects given a rebound from weak occupancy and pricing in a constrained supply environment coupled with Sunwest accretion.”
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care FacilitiesMorgan Keegan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!